ROBERT BOHNERT: Open Payments
NPI 1174293559 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,606 in 80 payments from 18 companies in 2025. Trend: 2023 $590 · 2024 $830 · 2025 $1,606
Food & beverage: $1,606
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $351 |
| ABBVIE INC. | 17 | $323 |
| PFIZER INC. | 12 | $191 |
| Regeneron Healthcare Solutions, Inc. | 3 | $108 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $105 |
| GENZYME CORPORATION | 2 | $95 |
| Madrigal Pharmaceuticals | 4 | $74 |
| Gilead Sciences, Inc. | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| QOL Medical, LLC | 2 | $37 |
Products named: ENTYVIO, DUPIXENT, RINVOQ, VELSIPITY, XIFAXAN, EOHILIA, REZDIFFRA, XELJANZ.
Industry payments across MO — which companies pay providers there.
